| Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/guidelines-for-the-submission-of-documentation-for-single-technology-assessment-sta-of-pharmaceuticals | Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals | The guidelines were last revised in October 2021. | 1933 | |
| Template for submission of documentation for the single technology assessment of pharmaceuticals | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/template-for-submission-of-documentation-for-the-single-technology-assessment-of-pharmaceuticals | Template for submission of documentation for the single technology assessment of pharmaceuticals | Documentation must be submitted in accordance with this templates and the submission guidelines. | 1935 | |
| Guidelines for pre-meetings in connection with single technology assessments (STAs) | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/guidelines-for-pre-meetings-in-connection-with-single-technology-assessments-stas | Guidelines for pre-meetings in connection with single technology assessments (STAs) | Pre-meetings with the Norwegian Medicines Agency (NoMA) are not obligatory, but may be arranged on request. | 1936 | Information to companies seeking guidance. |
| Pharmaceuticals for which the Regulation on Medicinal Products grants exceptions from the documentation requirements for single technology assessments (STAs) | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/pharmaceuticals-for-which-the-regulation-on-medicinal-products-grants-exceptions-from-the-documentation-requirements-for-single-technology-assessments-stas | Pharmaceuticals for which the Regulation on Medicinal Products grants exceptions from the documentation requirements for single technology assessments (STAs) | The following includes information on which pharmaceuticals that this concerns and the documentation that pharmaceutical companies must submit in order for the pharmaceutical to be assessed for public sector financing. | 1937 | Information on which pharmaceuticals that this concerns and the documentation necessary in order to be assessed for public sector financing. |
| Access to pharmaceuticals for very small patient groups with extremely severe conditions | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/access-to-pharmaceuticals-for-very-small-patient-groups-with-extremely-severe-conditions | Access to pharmaceuticals for very small patient groups with extremely severe conditions | The Norwegian Medicines Agency has prepared a memorandum that describes arrangements for the single technology assessment (STA) of pharmaceuticals for such patient groups. | 1938 | |
| FINOSE | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finose | FINOSE | FINOSE is a prosess for joint assessment. The Nordic collaboration FINOSE offers efficient and transparent evaluations of medicinal products with a view to reimbursement or procurement in the four countries Denmark, Finland, Norway and Sweden. | 3544 | |
| Unit cost database | https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/unit-cost-database | Unit cost database | This is an overview of unit costs to facilitate the work in health technology assessments (HTAs) and submission of documentation. The unit cost database has been revised as of 07.12.2021. | 1939 | |
